He M-M, Lo C-H, Wang K, et al. Immune-Mediated Diseases Associated With Cancer Risks. JAMA Oncol 2022; 8: 209–219. doi:10.1001/jamaoncol.2021.5680

Scharl S, Barthel C, Rossel J-B, et al. Malignancies in Inflammatory Bowel Disease: Frequency, Incidence and Risk Factors-Results from the Swiss IBD Cohort Study. Am J Gastroenterol 2019; 114: 116–126. doi:10.1038/s41395-018-0360-9

Simon TA, Thompson A, Gandhi KK, et al. Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis. Arthritis Res Ther 2015; 17: 212. doi:10.1186/s13075-015-0728-9

De Cock D, Hyrich K. Malignancy and rheumatoid arthritis: Epidemiology, risk factors and management. Best Pract Res Clin Rheumatol 2018; 32: 869–886. doi:10.1016/j.berh.2019.03.011

Wilton KM, Matteson EL. Malignancy Incidence, Management, and Prevention in Patients with Rheumatoid Arthritis. Rheumatol Ther 2017; 4: 333–347. doi:10.1007/s40744-017-0064-4

Szekanecz Z, Szekanecz E, Bakó G, et al. Malignancies in autoimmune rheumatic diseases - a mini-review. Gerontology 2011; 57: 3–10. doi:10.1159/000314634

Baecklund E, Askling J, Rosenquist R, et al. Rheumatoid arthritis and malignant lymphomas. Curr Opin Rheumatol 2004; 16: 254

Hellgren K, Baecklund E, Backlin C, et al. Rheumatoid Arthritis and Risk of Malignant Lymphoma: Is the Risk Still Increased? Arthritis Rheumatol Hoboken NJ 2017; 69: 700–708. doi:10.1002/art.40017

Keller DS, Windsor A, Cohen R, et al. Colorectal cancer in inflammatory bowel disease: review of the evidence. Tech Coloproctology 2019; 23: 3–13. doi:10.1007/s10151-019-1926-2

Zhou Q, Shen Z-F, Wu B-S, et al. Risk of Colorectal Cancer in Ulcerative Colitis Patients: A Systematic Review and Meta-Analysis. Gastroenterol Res Pract 2019; 2019: 5363261. doi:10.1155/2019/5363261

Fleury I, Chevret S, Pfreundschuh M, et al. Rituximab and risk of second primary malignancies in patients with non-Hodgkin lymphoma: a systematic review and meta-analysis. Ann Oncol Off J Eur Soc Med Oncol 2016; 27: 390–397. doi:10.1093/annonc/mdv616

Alping P, Askling J, Burman J, et al. Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients. Ann Neurol 2020; 87: 688–699. doi:10.1002/ana.25701

Emery P, Furst DE, Kirchner P, et al. Risk of Malignancies in Patients with Rheumatoid Arthritis Treated with Rituximab: Analyses of Global Postmarketing Safety Data and Long-Term Clinical Trial Data. Rheumatol Ther 2019; 7: 121–131. doi:10.1007/s40744-019-00183-6

Dupont-Lucas C, Leroyer A, Ley D, et al. Increased Risk of Cancer and Mortality in a Large French Population-Based Paediatric-Onset Inflammatory Bowel Disease Retrospective Cohort. J Crohns Colitis 2023; 17: 524–534. doi:10.1093/ecco-jcc/jjac166

Uchida T, Iwamoto N, Fukui S, et al. Comparison of risks of cancer, infection, and MACEs associated with JAK inhibitor and TNF inhibitor treatment: a multicentre cohort study. Rheumatology 2023; kead079. doi:10.1093/rheumatology/kead079

Axelrad JE, Lichtiger S, Yajnik V. Inflammatory bowel disease and cancer: The role of inflammation, immunosuppression, and cancer treatment. World J Gastroenterol 2016; 22: 4794–4801. doi:10.3748/wjg.v22.i20.4794

Danese S, Magro F, Hart A, et al. European Crohn´s and Colitis Organisation - ECCO - ECCO Standpoint on JAK inhibitors in IBD. . Im Internet: https://www.ecco-ibd.eu/publications/ecco-news/item/2022-2-ecco-standpoint-on-jak-inhibitors-in-ibd.html; Stand: 13.07.2023

Krause A, Krüger K. Deutsche Gesellschaft für Rheumatologie e.V. DGRh EV. Im Internet: https://www.dgrh.de/Start/Publikationen/Empfehlungen/Medi­kation/Januskinase-Inhibitoren-(JAKi).html; Stand: 13.07.2023

Galapagos NV. Jyseleca^® Fachinformation (Stand der Information: Mai 2023). 2023.